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Using saliva for disease diagnostics and health surveillance is a promising approach as collecting saliva is relatively easy
and non-invasive. Over the past two decades, using salivary biomarkers specifically for early cancer detection has
attracted much research interest, especially for cancers occurring in the oral cavity and oropharynx, for which the
five-year survival rate (62%) is still one of the lowest among all major human cancers. More than 90% of oral cancers
are oral squamous cell carcinoma (OSCC) and the standard method for detection is through a comprehensive clinical
examination by oral healthcare professionals. Despite the fact that the oral cavity is easily accessible, most OSCCs are
not diagnosed until an advanced stage, which is believed to be the major reason for the low survival rate, and points
to the urgent need for clinical diagnostic aids for early detection of OSCC. Thus, much research effort has been
dedicated to investigating potential salivary biomarkers for OSCC, and more than 100 such biomarkers have been
reported in the literature. However, some important issues and challenges have emerged that require solutions and
further research in order to find reliable OSCC salivary biomarkers for clinical use. This review article provides an
up-to-date list of potential OSCC salivary biomarkers reported as of the fall of 2013, and discusses those emerging
issues. By raising the awareness of these issues on the part of both researchers and clinicians, it is hoped that reliable,
specific and sensitive salivary biomarkers may be found soon—and not only biomarkers for early OSCC detection but
also for detecting other types of cancers or even for monitoring non-cancerous disease activity.
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Worldwide, cancers of the oral cavity and pharynx are the
6th most common type [1]. Although the incidence of oral
and pharyngeal cancers is not considered high in the US
(it accounts for approximately 3% of all malignancies in
men and 2% of those in women) [1]– its five-year survival
rate has remained around 62%– in contrast to the five-
year survival rates for breast cancer (89%) and prostate
cancer (99%) [2]. More than 90% of the oral cancers are
squamous cell carcinomas (OSCC), which arise from the
epithelial lining of the oral cavity. Even though the oral
cavity is easily accessible for direct visual examination,
most OSCCs are not diagnosed until an advanced stage,
which is believed to be the major reason for the low sur-
vival rate. This underscores the importance of early and
accurate detection by clinicians, as well as the need to* Correspondence: ycheng@bcd.tamhsc.edu
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in any medium, provided the original work is peducate the public about oral cancer risk factors and
prevention.
In responding to the call for early detection of OSCC,
several diagnostic adjuncts have been developed, or cur-
rently are in development, including the use of salivary
biomarkers [3-5]. Saliva has been found to contain constit-
uents that reflect the diseased or physiological state of the
human body, and hence could be utilized for diagnostic
purposes [6-8]. The search for reliable salivary biomarkers
for early detection of OSCC has developed rapidly,
spurred on by the fact that collecting saliva is relatively
easy and non-invasive, compared to the drawing of blood.
From the late 1990s until the present, more than 40 re-
search studies have been published and more than 100 dif-
ferent salivary constituents have been suggested as
potential OSCC salivary biomarkers (see Table 1). Several
excellent reviews have been previously published concern-
ing the basis for salivary diagnostics, and the history and
evolution of salivary proteomic, transcriptomic, genomic,
and metabolomic research for oral cancer detectionn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Table 1 Potential salivary biomarkers for oral cancer detection, reported as of 2013
Category Potential OSCC salivary biomarkers Authors/year
Non-organic compound Na, Ca, F, and Mg Shpitzer et al./2007 [55]
Peptide Defensin-1 Mizukawa et al./1998 [28]
Proteins P53 autoantibody Warnakulasuriya et al./2000 [19]
α-amylase Chen et al./2002 [20]
IL-8 St. John et al./2004 [23]
Rhodus et al./2005 [24]
Arellano-Garcia et al./2008 [70]
Brinkmann et al./2011 [43]
Elashoff et al./2012 [44]
TNF-α Rhodus et al./2005 [24]
IL-1
IL-6 Rhodus et al./2005 [24]
Katakura et al./2007 [34]
Saheb-Jamee et al./2008 [35]
Sato et al./2010 [36]
Cheng et al./2013 [38]
Basic fibroblast growth factor Vucicevic et al./2005 [27]
Gorugantula et al./2012 [39]
Statherin Contucci et al./2005 [62]
Cyfra 21.1 Nagler et al./2006 [25]
Tissue polypeptide antigen (TPA)
Cancer antigen 125 (CA125) Nagler et al./2006 [25]
Balan et al./2012 [57]
Endothelin-1 Pickering et al./2007 [21]
Cheng et al./2011 [40]
IL-1β Katakura et al./2007 [34]
Brinkmann et al./2011 [43]
Elashoff et al./2012 [44]
CD44 Franzmann et al./2007 [46]
Total salivary protein Shpitzer et al./2007 [55]
Insulin growth factor 1 (IGF-1)
MMP-2
MMP-9 Shpitzer et al./2007, 2009 [49,55]




M2BP Hu et al./2008 [29]
Brinkmann et al./2011 [43]
Elashoff et al./2012 [44]
Carcinoembryonic antigen (CEA) He et al./2009 [54]
Carcinoma associated antigen CA-50
Salivary carbonyls Shipitzer et al./2009 [49]
Cyclin D1
Maspin
8-oxoguanine DNA glycosylase (OGG1)
Phosphorylated-Src
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Ki-67
Lactate dehydrogenase Shipitzer et al./2009 [49]
Shetty et al./2012 [58]
Transferrin Jou et al./2010 [45]
Zinc finger protein 501 peptide Jou et al./2011 [60]





DNAs P53 gene codon 63 Liao et al./2000 [18]
Loss of heterozygosity in the combination of
markers D3S1234, D9S156, and D17S799
El-Naggar et al./2001 [51]
Mitochondrial DNAs (cytochrome c oxidase I
and cytochrome c oxidase II)
Jiang et al./2005 [37]
Hypermethylation of promoters in tumor
suppressor genes: DAPK, DCC, MINT-31,
TIMP-31, TIMP-3, p16, MGMT, CCNA1
Carvalho et al./2011 [61]
mRNAs IL-8 Li et al./2004 [22]
Brinkmann et al./2011 [43]
Elashoff et al./2012 [44]
IL-1β Li et al./2004 [22]
Elashoff et al./2012 [44]
DUSP1 (dual specificity phosphatase 1) Li et al./2004 [22]
Elashoff et al./2012 [44]
Cheng et al./2013 [41]
H3F3A (H3 histone family 3A) Li et al./2004 [22]
Elashoff et al./2012 [44]
OAZ1 (ornithin decarboxylase antizyme 1) Li et al./2004 [22]
Elashoff et al./2012 [44]
Cheng et al./2013 [41]
S100P (S100 calcium binding protein P) Li et al./2004 [22]
Brinkmann et al./2011 [43]
Elashoff et al./2012 [44]
Cheng et al./2013 [41]
SAT (spermidine/spermine N1-acetyltransferase EST) Li et al./2004 [22]
Brinkmann et al./2011 [43]
Elashoff et al./2012 [44]
MicroRNAs miR-125a Park et al./2009 [31]
miR-200a
miR-31 Liu et al./2012 [33]
Long non-coding RNAs HOTAIR Tang et al./2013 [56]
Oxidative stress-related molecules Reactive nitrogen species (RNS) such as nitric
oxide (NO), nitrites (NO2) and nitrates (NO3)
Bahar et al./2007 [26]
Peroxidase Bahar et al./2007 [26]
Glutathione S-transferase (GST) Bahar et al./2007 [26]
Superoxide dismutase (SOD) Agha-Hosseini et al./2012 [52]
8-hydroxy-2-deoxyguanosine (8-OHdG)
Glutathione Almadori et al./2007 [30]
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Table 1 Potential salivary biomarkers for oral cancer detection, reported as of 2013 (Continued)
Malondialdehyde (MDA) Agha-Hosseini et al./2012 [52]
Glucocorticoid Cortisol Bernabé et al./2012 [53]
Metabolomics Cadaverine, alpha-aminobutyric acid, alanine,
C5H14N5, piperidine, taurine piperideine,
pipercolic acid, C4H9N, C8H9N, pyrroline
hydroxycarboxylic acid, betaine, C6H6N2O2,
leucine+isoleucine, tyrosine, histidine,
tryptophan, beta-alanine, glutamic acid,
threonine, serine, glutamine, choline,
carnitine, C4H5N2O11P
Sugimoto et al./2010 [47]
Phenylalanine Wei et al./2011 [48]
Sugimoto et al./2010 [47]
Valine Wei et al./2011 [48]
Sugimoto et al./2010 [47]
Lactic acid Wei et al./2011 [48]
Glycosylation-
related molecules
Sialic acid Vajaria et al./2013 [32]
α-L-fucosidase
Other Telomerase activity Zhong et al./2005 [50]
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list of potential OSCC salivary biomarkers, as of the fall of
2013, and will focus on some emerging issues/challenges
that seem to be major roadblocks on the way to bringing
reliable salivary biomarkers into actual clinical use. The
intention of this review is to increase awareness of these
issues on the part of both researchers and clinicians, with
the hope that good solutions may be generated more
quickly by group efforts in this field. Addressing these is-
sues not only will serve to accelerate progress toward
finding reliable salivary biomarkers for early OSCC de-
tection, but also should have a positive effect on the
search of reliable salivary biomarkers for other types of
cancer detection or even for monitoring non-cancerous
disease activity.
Review
Whole saliva (oral fluid) is unique and complex, both in
its sources and composition. It consists not only of se-
cretions from the three major salivary glands (parotid,
submandibular and sublingual) and the minor glands,
but also gingival crevicular fluid, oral mucosa transudate,
secretions from nasal and pharyngeal mucosa, non-
adherent bacteria, desquamated oral epithelial cells,
keratin debris, blood cells, and perhaps food or medica-
tion residuals [8]. The functions of saliva include lubri-
cation, digestion, antimicrobial activity, facilitating
remineralization of the tooth enamel, and maintaining
normal taste sensation [15]. These important functions
are achieved by the various chemical components of sal-
iva including water, inorganic compounds (ions), organic
compounds (non-proteins and lipids), protein/polypep-
tides, and hormones [15]. Salivary proteins and polypep-
tides constitute a significant portion of the mix, and playan important role in carrying on the main functions of
saliva. So far, more than 2300 proteins and peptides have
been found in human saliva [16]. The most abundant
proteins are α-amylase, albumin, cystatins, hystatins,
secretory-IgA, lactoferrin, mucins, lysozymes, proline
rich proteins, statherin and transferrin–which together
account for more than 98% of the total salivary proteins
[15,17]. Most of the potential OSCC salivary biomarkers
are also salivary proteins (see Table 1). However, except
for three, α-amylase, statherin, and transferrin, those
proteins, as well as the non-protein OSCC salivary
biomarker candidates, are present in a very low concentra-
tion in saliva and require methods/instruments with high
sensitivity for detection.
Reported potential salivary biomarkers for oral cancer
detection
So far, more than 100 potential OSCC salivary biomarkers
have been reported in the literature, based mainly on com-
paring the levels found in OSCC patients to the levels
found in non-OSCC normal controls (see Table 1) [18-62].
Some of these potential OSCC salivary biomarkers have
been investigated by more than one research group; how-
ever, in some studies, no significant differences have been
found in IL-6 [23], IL-8 [34,35] and endothelin-1 [63]
levels between the OSCC patients and their respective
control groups.
The research methodology involved so far in investi-
gating these potential OSCC salivary biomarkers can be
grouped according to the types of biomarker, as follows:
1. Non-organic compound biomarkers
Flame photometry, atomic absorption, and
spectrophotometry [55]
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High performance liquid chromatography (HPLC)
[28,62]
Enzyme-linked immunosorbent assay (ELISA)
[19,21,23,24,27,34-36,39,40,46,49,54,55,57]
Radio-immunoassay [25]
Two-dimensional gel electrophoresis (2DE), followed
by mass spectrometry (MS) [59]
2DE and reverse-phase liquid chromatography (LC),
followed by LC-tandem MS [29]
Matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry (MALDI-TOF MS) [20,60]
2DE followed by MALDI-TOF MS [45]
3. DNA, mRNA or microRNA biomarkers
Polymerase chain reaction (PCR) [18,37,51]
Quantitative PCR (qPCR) [31,33,41-44,56]
Microarrays followed by qPCR [22]
4. Metabolomic biomarkers
Capillary electrophoresis TOF MS [47]
HPLC with quadrupole/TOF MS [48]
5. Miscellaneous biomarkers (chemical and enzyme
activity)
HPLC [30]
Colorimetric (mostly commercially available) assays
[26,32,49,50,52,53,58]
Most OSCC salivary biomarker research has involved
investigating the constituents of the whole saliva in an
unstimulated state, although two studies did investigate
the stimulated saliva samples [28,36]. After a saliva sam-
ple is collected, a centrifugation processing procedure is
often performed to remove the solid constituents (des-
quamated oral epithelial cells, keratin debris, blood cells,
bacteria and food residuals, if any), but some studies ap-
pear to have analyzed the whole saliva content without
centrifugation [46,54,58,63,64]. After separating out
those solid constituents, samples were often stored in a
frozen state until further analysis. Most salivary bio-
marker research studies have investigated only the
supernatant (cell-free) portion of the saliva samples,
while other studies investigated only the pellet portion
of the saliva [50,51,61] or both the supernatant and the
pellet portions [49] after centrifugation.
Issues/challenges in OSCC salivary biomarker research
1. A lack of standardization of conditions and methods of
saliva sample collection, processing, and storage
Despite the fact that more than 100 potential OSCC saliv-
ary biomarkers have been reported, there has been no
standardization regarding the condition of the subjects
from whom the saliva samples are collected (e.g., the tim-
ing in regard to prior food and drink intake, or the use of
oral hygiene products). Similarly, a uniform method has
not been established for how the saliva samples arecollected, processed and stored prior to measurement and
comparison of the biomarker levels in the groups studied.
For example, in regard to participant requirements at
the time of saliva collection, all researchers collected saliva
samples in the morning, yet some researchers collected
saliva samples from participants at least one hour after
food intake [23,25,26,63]; some collected saliva at least 1
1/2 hours after food intake [24]; and in ours and another
study, we collected saliva in the morning before the partic-
ipants ate, drank or performed any oral hygiene proce-
dures [30,39-41]. In regard to saliva processing methods,
most investigators centrifuged the saliva samples immedi-
ately after collection. However, they carried out this pro-
cedure with various degrees of centrifugal force and for
various lengths of time, such as 800 g for 10 minutes
[25,26,49]; 2000 g for 10 minutes [52]; 2600 g for 15 mi-
nutes [23,32,40,41,43]; 14,000 g for 20 minutes [59];
2000 rpm (gravity not specified) for 5 minutes [53];
3500 rpm (gravity not specified) for 15 minutes [34];
14,000 rpm (gravity not specified) for 20 minutes [21].
Others stored the whole saliva samples at −80°C immedi-
ately after collection, then later thawed and centrifuged
the samples at 4500 g for 20 minutes [35] or 6000 rpm
(gravity not specified) for 20 minutes [24]. In regard to sal-
iva sample preservation, we and some other investigators
added proteinase inhibitors or RNase inhibitors to preserve
salivary proteins and RNAs, respectively [22,29,39-41], but
most investigators did not add any inhibitors. In regard to
saliva sample storage, most researchers stored the saliva
samples in −80°C, although others stored samples at −20°C
[28,52,54] or 4°C [30].
The differences in these factors among the different
studies raises the question as to whether the levels of
the potential OSCC salivary biomarkers reported in any
one lab could be compared to the levels of the same
biomarker reported in any other lab. In fact, for the re-
ported potential biomarkers which have been investi-
gated by more than one study, a wide variability was
found in the levels of both the diseased and the control
groups among different labs, and the different methods
used for collecting and handling the saliva samples are
likely to be one of the reasons for that variability. As re-
search efforts will continue to be devoted to this promis-
ing field, standardization of saliva collection, processing and
storage methods is essential, so that all the research find-
ings among different research groups can be compared and
validated, and progress accelerated toward finding the most
reliable validated OSCC salivary biomarkers. Without such
standardization and validation of biomarkers, valuable re-
search resources are being squandered, because reported
results cannot be translated into the desired clinical use
and patient outcomes. A panel of experts in this research
field is needed to discuss this issue and find a way to estab-
lish the standards needed.
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biomarkers in both non-cancerous individuals and OSCC
patients, suggest unknown confounding factors
The wide variations noted in the reported levels of some
of the salivary biomarker candidates among different re-
search labs obviously creates difficulties in determining
the reference level and the OSCC level for any given po-
tential OSCC salivary biomarker. For example, salivary IL-
6 and IL-8 are two of the most studied biomarkers, not
only for potential OSCC detection but also for monitoring
disease activity of chronic periodontitis and oral lichen
planus (OLP)–a chronic mucocutaneous inflammatory
disease that affects about 2% of the world population
[65,66]. As can be seen in Table 2 [23,24,34,35,38,67-72],
wide variations in the reported salivary IL-6 and IL-8
levels among the different studies were noted even in the
healthy controls, with the average IL-6 levels ranging from
1.4 ± 0.9 pg/ml [24] to 47.46 ± 18.74 pg/ml [67], and IL-8
levels ranging from 250 pg/ml [23,34,35] to 1945 ±
181 pg/ml [68]. When the reference levels vary so much
among the different studies, it is impossible to determine
what ranges of salivary IL-6 or IL-8 levels are likely to in-
dicate OSCC development. For example, the average saliv-
ary IL-8 levels found in OSCC patients in two studies
were 720 pg/ml [23] and 1093.7 ± 1089.0 pg/ml [35], re-
spectively –in contrast to 250 pg/ml and 700.7 ±
1031.5 pg/ml, respectively, in healthy controls. The aver-
age salivary IL-8 levels found in chronic periodontitis and
healthy controls reported by Teles et al.[68] were 2268 ±
111 and 1945 ±181 pg/ml, respectively, both of which
would most likely be considered in the concentration
range for OSCC by the two previous studies reported by
St John et al. [23] and SahebJamee et al. [35].
These wide variations in the levels of the same salivary
constituent across the different research studies could be
due at least partly to the different processing methods
used, as described above. However, they may also pos-
sibly be due to inherent biological variations within dif-
ferent individuals and groups. In fact, some studies have
reported intra- and inter-subject variability in salivary
proteome and in specific potential OSCC salivary pro-
tein and mRNA biomarkers in studies of healthy adults
[73-75]. Inherent biological variations are known to cre-
ate difficulties in determining the reference values for
biological samples in clinical laboratories [76]. Such vari-
ations in salivary constituents could be attributed to dif-
ferences in ethnic background, geographic locations, age,
gender, non-neoplastic systemic diseases, dietary habits,
medications being taken or other factors. For example,
significantly increased levels in one of the potential saliv-
ary OSCC salivary biomarkers, endothein-1, have been
reported in patients with chronic heart failure [77] or
upper gastrointestinal diseases such as gastric ulcer, duo-
denal ulcer and gastritis [78] in the absence of OSCC.Age-related reduction in the concentrations of certain sal-
ivary proteins [79,80] has also been reported, although
whether there are any significant age-related changes in
any of the reported potential OSCC salivary biomarkers
has not been determined. In summary, the intra- and
inter-subject variability points to an urgent need for more
research regarding possibly underlying causes for these in-
herent biological variations, in order to refine and deter-
mine the appropriate reference range for any potential
OSCC salivary biomarkers.
3. The need for further validation of OSCC salivary
biomarkers
Validation in the presence of common oral inflamma-
tory conditions Ideally, a good clinical test requires high
sensitivity and specificity. The oral cavity is commonly
subject to inflammation from a variety of causes, including
trauma, dental plaque, infection and certain mucocutane-
ous inflammatory diseases. Whether such oral inflamma-
tion (non-neoplastic conditions) affects the levels of the
potential OSCC salivary biomarkers is essentially un-
known, because most studies have investigated the poten-
tial salivary biomarker levels only in OSCC patients and
non-OSCC controls, without regard for other inflamma-
tory conditions that might have been present [9,21-27]. If
the levels of any of the potential OSCC salivary bio-
markers are increased in the presence of oral inflamma-
tion to a degree that there is no significant difference
between those levels and the levels found in OSCC pa-
tients, it would result in a high false positive rate and
greatly reduce the value of that biomarker in clinical use
for OSCC detection.
In review of the reported potential OSCC salivary bio-
markers, many of them– such as IL-6 [24,34,35], IL-8
[23,24,70], IL-1β [22,70], basic fibroblast growth factor
[27], and molecules related to oxidative stress–[26,30] are
known to be important factors involved in inflammation
and/or wound healing [81,82]. Indeed, the levels of some
of these salivary constituents have been reported to be sig-
nificantly higher or lower in periodontitis or OLP patients
who did not have OSCC [67,69,71,72,83,84]. Therefore, re-
search that validates any potential OSCC salivary bio-
marker with individuals having common non-neoplastic
oral inflammatory diseases is necessary in order to estab-
lish the reliability of that salivary OSCC biomarker.
Validation in the presence of other types of human
cancers The advantages (being non-invasive and easy to
collect) of using saliva over blood for disease detection
and monitoring of disease progression encourage saliv-
ary biomarker research activities not only for OSCC de-
tection but also for detection of other types of cancers.
For instance, several potential salivary biomarkers for
breast and lung cancer detection have been reported in
Table 2 Salivary Concentrations of IL-6 and IL-8 (pg/ml) in OSCC, OLP, and chronic periodontitis patient groups
Author/reographical region/year OSCC OLP Chronic periodontitis Controls
IL-6 IL-8 IL-6 IL-8 IL-6 IL-8 IL-6 IL-8
St. John et al./California, USA/2004 [23] 720 250
Rhodus et al./Minnesota, USA/2005 [24] 88.2± 43.2 3154.1±1023.2 1.4±0.9 1580± 789
Rhodus et al./Minnesota, USA/2005 [67] 371.35±205.52 2194.3± 496.7 47.46±18.74 703.8± 131.6
Katakura et al./Tokyo, Japan/2007 [34] 86.5 720 0 250
Zhang et al./Sichuan, China/2008 [69] 48.79±8.53 1737.49±1073.54 29.9±4.68 641.46±172.91
Saheb Jamee et al./Tehran, Iran/2008 [35] 40.9± 79.5 1093.7±1089.0 2.5±1.3 700.7± 1031.5
Arellano- Garcia et al./California, USA/2008 [70] 3347.7±2929 759.4± 563
Teles et al./Massachusetts, USA/2009 [68] 2268±111 1945±181
Sharma et al./Manipal, India/2011 [71] 311.35±11.51 17.15±8.44
Ebersole et al./Kentucky, USA/2013 [72] 35.57±48.17 3.30±2.32
Cheng et al./Texas, USA/2014 [38] 178.41±172.32 1525.33±1123.95 20.74±22.28 1328.37±731.80 5.85±4.02 738.79±394.00 4.92±8.77 890.83±563.22
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markers for breast carcinomas, such as CA125 [91],
haptoglobin, profilin-1 and transferrin [87]; and one re-
ported salivary biomarker for lung cancer, S100 calcium
binding protein A9 [86], are the same ones reported as
potential OSCC salivary biomarkers [25,29,57,59]. Saliv-
ary annexin A1, carbonic anhydrase VI, S100 calcium
binding protein, and lipocalin have also been reported as
potential biomarkers for both breast and lung cancers
[86,87]. These findings suggest that the levels of at least
some salivary constituents could be significantly changed
by the presence of more than one type of cancer, a fact
which points to the necessity of validating the specificity
of the reported potential OSCC salivary biomarkers with
patients who have other types of cancers.
Conclusion
Salivary biomarkers represent a promising non-invasive
approach for oral cancer detection, and an area of strong
research interest. However, some issues/challenges have
arisen that need to be resolved in order to establish this
approach as a reliable, highly sensitive and specific
method for clinical use. These issues include a lack of
standardization for saliva sample collection, processing,
and storage; wide variability in the levels of potential
OSCC salivary biomarkers in both non-cancerous indi-
viduals and OSCC patients; and a need for further valid-
ation of OSCC salivary biomarkers with individuals who
have either a chronic oral inflammatory disease or other
types of cancers, but do not have OSCC. These issues
call for convening a panel of researchers in this field to
aim for eventual standardization, plus further research,
especially concerning biological variance and physio-
logical changes affecting the potential oral cancer saliv-
ary biomarkers. The experience gained in OSCC salivary
biomarker research also can serve as an important refer-
ence in salivary diagnostics, including identifying, valid-
ating, and applying salivary biomarkers for other types
of cancer detection and for monitoring non-cancerous
disease activity.
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